Porphyria Cutanea Tarda Clinical Trial
Official title:
“Factors Associated With Porphyria Cutanea Tarda in Patients Infected With Hepatitis C Virus”
Comparison of patients with documented PCT and HCV infection, documented PCT without HCV,
HCV infection without PCT and controls without HCV or PCT.
Single blood + urine sample uptake to investigate : mutations in HFE gene, uroporphyrinogen
decarboxylase activity, HCV genotye, history of disease.
n/a
Observational Model: Case Control, Time Perspective: Longitudinal
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03118674 -
Harvoni Treatment Porphyria Cutanea Tarda
|
Phase 2 | |
Completed |
NCT00005103 -
Study of the Pathogenesis of Porphyria Cutanea Tarda
|
N/A | |
Completed |
NCT01573754 -
Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda
|
Phase 2 | |
Recruiting |
NCT01284946 -
Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda
|
Phase 2 | |
Completed |
NCT00599326 -
Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda
|
Phase 3 |